Chilton Capital Management LLC Sells 77,653 Shares of Stryker Corporation $SYK

Posted by Francis Steltz on Aug 15th, 2026

Chilton Capital Management LLC decreased its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 95.8% during the second quarter, HoldingsChannel.com reports. The fund owned 3,426 shares of the medical technology company’s stock after selling 77,653 shares during the period. Chilton Capital Management LLC’s holdings in Stryker were worth $1,079,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Sankala Group LLC acquired a new stake in Stryker in the 4th quarter worth approximately $26,000. Godfrey Financial Associates Inc. acquired a new position in Stryker during the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC acquired a new position in Stryker during the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker in the fourth quarter valued at approximately $28,000. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

SYK has been the subject of several recent analyst reports. BTIG Research decreased their price objective on shares of Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a report on Friday, July 31st. Needham & Company LLC dropped their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Citigroup reiterated a “buy” rating on shares of Stryker in a report on Thursday. Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Finally, UBS Group assumed coverage on shares of Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Check Out Our Latest Report on Stryker

Stryker Trading Down 0.7%

Shares of SYK stock opened at $338.80 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The firm’s fifty day simple moving average is $324.61 and its 200 day simple moving average is $333.57. The firm has a market capitalization of $129.95 billion, a P/E ratio of 35.11, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter last year, the company earned $3.13 earnings per share. The firm’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

About Stryker

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.